Newsletters
Dr. Weisman participates in FDA Advisory Committee
The committee convened to discuss tofersen, an experimental injection for treatment of ALS.
ANA administers first lecanemab infusion in PA
Leqembi significantly reduces progression of memory loss in those with Alzheimer’s disease by about 30%.
Dr. Weisman Quoted in Philadelphia Inquirer Article on Lecanemab
Blood tests for Alzheimer’s biomarkers will be a powerful tool in determining who will benefit from a drug.
Dr. Weisman Quoted in NY Times Article on Aducanumab
Medicare should require safety monitoring and medical expertise in the use of aducanumab.
Aducanumab: Neither Far Nor Deep
While we might not have clear progress, we do have an advance.
Alzheimer’s Disease: Mystery No More
It was once so common to be forgetful in old age that it was thought to be normal. But normal aging only includes things like tip-of-tongue memory loss and forgetting faces.